Regulatory approval

Published by the Health Service Executive. Approved

Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Pertuzumab - ODMS; Trastuzumab, Carboplatin, and Paclitaxel - N/A

Citation

Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2), 2024, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6662/775_v3_Pertuzumab_trastuzumab_PACLitaxel_CARBOplatin.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab